Diagnosis and treatment of primary aldosteronism

Reviews in Endocrine and Metabolic Disorders

Volumn 12, Issue 1, 2011, Pages 27-36

  Rossi, Gian Paolo D ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Aldosterone; Arterial hypertension; Diagnosis; Primary aldosteronism; Treatment

Indexed keywords

6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; ALDOSTERONE; ALDOSTERONE SYNTHASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANRENOATE POTASSIUM; CANRENONE; CAPTOPRIL; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; EPLERENONE; FLUDROCORTISONE; HYDROCORTISONE; OXYGENASE INHIBITOR; POTASSIUM; PRORENIN; RENIN; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADENOMA; ADRENAL INCIDENTALOMA; ADRENAL VEIN SAMPLING; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE PRODUCING ADENOMA; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CAPTOPRIL CHALLENGE TEST; CORTICOTROPIN TEST; CRYOPRESERVATION; CUSHING SYNDROME; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUDROCORTISONE WITH SALT LOADING TEST; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; HYPOKALEMIA; LAPAROSCOPIC SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL SODIUM LOADING TEST; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PREDICTIVE VALUE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; RECEIVER OPERATING CHARACTERISTIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALINE INFUSION TEST; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

ADRENALECTOMY; HUMANS; HYPERALDOSTERONISM;

EID: 79956119132     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-011-9162-8     Document Type: Review

References (110)

1. Kucharz EJ. Forgotten description of primary hyperaldosteronism. Lancet. 1991;337:1490.
2. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3-17.
3. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964;107:159-72.
4. Rossi GP. Surgically correctable hypertension caused by primary aldosteronism. Best Pract Res Clin Endocrinol Metab. 2006;20:385-400. (Pubitemid 44356451)
5. Fritsch NM, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep. 2003;5:59-65. (Pubitemid 38898933)
6. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42:49-55. (Pubitemid 36849598)
7. Schupp N, Queisser N, Wolf M, Kolkhof P, Barfacker L, Schafer S, et al. Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists. Horm Metab Res. 2010.
8. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802-10.
9. Brilla CG, Maisch B, Weber KT. Myocardial collagen matrix remodelling in arterial hypertension. Eur Heart J. 1992;13(Suppl D):24-32.
10. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-64.
11. Rossi GP, Sacchetto A, Pavan E, Scognamiglio R, Pietra M, Pessina AC. Left ventricular systolic function in primary aldosteronism and hypertension. J Hypertens. 1997;19 Suppl 8:S147-51.
12. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997;95:1471-8. (Pubitemid 27142805)
13. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23-7. (Pubitemid 34755974)
14. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond). 2002;103:425-31. (Pubitemid 35193248)
15. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109:2857-61. (Pubitemid 38780298)
16. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-33. (Pubitemid 23166942)
17. Muiesan ML, Rizzoni D, Salvetti M, Porteri E, Monteduro C, Guelfi D, et al. Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens. 2002;20:1439-44. (Pubitemid 34925690)
18. Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol. 1998;32:985-92. (Pubitemid 28459589)
19. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis. 1999;33:261-6. (Pubitemid 29072226)
20. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens. 1995;13:1801-2. (Pubitemid 26015820)
21. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY study. Hypertension. 2006;48:232-8. (Pubitemid 44309817)
22. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab. 2008;19:88-90. (Pubitemid 351442920)
23. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2638-45. (Pubitemid 43882339)
24. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Investig. 1995;18:370-3.
25. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-8. (Pubitemid 40523144)
26. Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135:258-61. (Pubitemid 32799339)
27. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension. 2008;51:1366-71. (Pubitemid 351555951)
28. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911-8. (Pubitemid 350287534)
29. Conn JW. Primary aldosteronism. In: Hypertension: pathophysiology and treatment. New York: McGraw-Hill; 1977.
30. Conn JW. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1990;116:253-67.
31. Conn JW. Plasma renin activity in primary aldosteronism. JAMA. 1964;190:222-5.
32. Conn JW. A concluding response. Arch Intern Med. 1969;123:154-5.
33. Rossi GP. Primary aldosteronism: a needle in a haystack or a yellow cab on fifth avenue? Curr Hypertens Rep. 2004;6:1-4.
34. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens. 2008;26:613-21. (Pubitemid 351354903)
35. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol. 1993;20:296-8. (Pubitemid 23140199)
36. Anderson Jr GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609-15. (Pubitemid 24192887)
37. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994;21:315-8. (Pubitemid 24201225)
38. Abdelhamid S, Muller-Lobeck H, Pahl S, Remberger K, Bonhof JA, Walb D, et al. Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch Intern Med. 1996;156:1190-5. (Pubitemid 26197664)
39. Brown MA, Cramp HA, Zammit VC, Whitworth JA. Primary hyperaldosteronism: a missed diagnosis in 'essential hypertensives'? Aust N Z J Med. 1996;26:533-8.
40. Rossi GP, Rossi E, Pavan E, Rosati N, Zecchel R, Semplicini A, et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf). 1998;49:713-23. (Pubitemid 29009500)
41. Mosso L, Fardella C, Montero J, Rojas P, Sanchez O, Rojas V, et al. High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension. Rev Med Chile. 1999;127:800-6.
42. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J. 2000;90:394-400. (Pubitemid 30303558)
43. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000;85:2854-9. (Pubitemid 32269163)
44. Denolle T, Hanon O, Mounier-Vehier C, Marquand A, Fauvel JP, Laurent P, et al. What tests should be conducted for secondary arterial hypertension in hypertensive patients resistant to treatment? Arch Mal Coeur Vaiss. 2000;93:1037-9.
45. Cortes P, Fardella C, Oestreicher E, Gac H, Mosso L, Soto J, et al. Excess of mineralocorticoids in essential hypertension: clinical-diagnostic approach. Rev Med Chile. 2000;128:955-61.
46. Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother. 2000;54 Suppl 1:83s-5.
47. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863-7. (Pubitemid 32269290)
48. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens. 2000;14:311-5. (Pubitemid 30311512)
49. Rayner BL, Myers JE, Opie LH, Trinder YA, Davidson JS. Screening for primary aldosteronism-normal ranges for aldosterone and renin in three South African population groups. S Afr Med J. 2001;91:594-9. (Pubitemid 32707864)
50. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-6. (Pubitemid 35434912)
51. Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem. 2002;48:1919-23. (Pubitemid 35222749)
52. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens. 2002;15:896-902. (Pubitemid 35168429)
53. Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci. 2007;44:1-85. (Pubitemid 44973616)
54. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-81.
55. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1, 125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-300. (Pubitemid 44873058)
56. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43:518-24. (Pubitemid 38282420)
57. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008.
58. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab. 2005;16:114-9. (Pubitemid 40432461)
59. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem. 1991;37:1811-9. (Pubitemid 121000617)
60. Roding JH, Weterings T, van der Heiden C. Plasma renin activity: temperature optimum at approximately 45 degrees C. Clin Chem. 1997;43:1243-4. (Pubitemid 27297273)
61. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab. 2005;16:86-91. (Pubitemid 40432456)
62. Campbell DJ, Nussberger J, Stowasser M, Danser AH, Morganti A, Frandsen E, et al. Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem. 2009;55:867-77.
63. Rossi GP, Barisa M, Belfiore A, Desideri G, Ferri C, Letizia C, et al. The aldosterone renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens, in press. 2010.
64. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40:897-902. (Pubitemid 35434913)
65. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst. 2001;2:156-69. (Pubitemid 33685887)
66. Rossi GP, Rossi E, Pavan E, Rosati N, Zecchel R, Semplicini A, et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf). 1998;49:713-23. (Pubitemid 29009500)
67. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens. 2003;21:2149-57.
68. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens. 2006;24:737-45.
69. Gleason PE, Weinberger MH, Pratt JH, Bihrle R, Dugan J, Eller D, et al. Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia. J Urol. 1993;150:1365-8. (Pubitemid 24356173)
70. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-50. (Pubitemid 38368386)
71. Calo LA, Pagnin E, Davis PA, Armanini D, Mormino P, Rossi GP, et al. Oxidative stress-related proteins in a Conn's adenoma tissue. Relevance for aldosterone's prooxidative and proinflammatory activity. J Endocrinol Investig. 2010;33:48-53.
72. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension. 2001;37:1440-3. (Pubitemid 34225389)
73. Castro OL, Yu X, Kem DC. Diagnostic value of the post-captopril test in primary aldosteronism. Hypertension. 2002;39:935-8. (Pubitemid 34437553)
74. Irony I, Kater CE, Biglieri EG, Shackleton CH. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens. 1990;3:576-82.
75. Gordon RD, Gomez-Sanchez CE, Hamlet SM, Tunny TJ, Klemm SA. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (iha:adrenal hyperplasia) or low-renin hypertension. J Hypertens Suppl. 1987;5 suppl 5:S103-6.
76. Rossi GP, Seccia TM, Palumbo G, Belfiore A, Bernini G, Caridi G, et al. Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism. Hypertension. 2010;55:83-9.
77. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension. 1984;6:717-23. (Pubitemid 15210514)
78. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, et al. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension. 2007;50:424-31. (Pubitemid 47205795)
79. Gordon RD. Primary aldosteronism. J Endocrinol Investig. 1995;18:495-511.
80. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst. 2001;2:156-69. (Pubitemid 33685887)
81. Goh BK, Tan YH, Chang KT, Eng PH, Yip SK, Cheng CW. Primary hyperaldosteronism secondary to unilateral adrenal hyperplasia: an unusual cause of surgically correctable hypertension. A review of 30 cases. World J Surg. 2007;31:72-9. (Pubitemid 46089546)
82. Rossi GP, Chiesura-Corona M, Tregnaghi A, Zanin L, Perale R, Soattin S, et al. Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism. J Hum Hypertens. 1993;7:357-63. (Pubitemid 23243382)
83. Rossi GP, Vendraminelli R, Cesari M, Pessina AC. A thoracic mass with hypertension and hypokalaemia. Lancet. 2000;356:1570.
84. Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer. 2005;12:149-59. (Pubitemid 40477095)
85. Omura M, Sasano H, Fujiwara T, Yamaguchi K, Nishikawa T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism. 2002;51:350-5. (Pubitemid 34232637)
86. Fallo F, Barzon L, Boscaro M, Sonino N. Coexistence of aldosteronoma and contralateral nonfunctioning adrenal adenoma in primary aldosteronism. Am J Hypertens. 1997;10:476-8. (Pubitemid 27195986)
87. Magill SB, Raff H, Shaker JL, Brickner RC, Knechtges TE, Kehoe ME, et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab. 2001;86:1066-71. (Pubitemid 32322983)
88. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85:637-44.
89. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136:1227-35. (Pubitemid 39647538)
90. Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009;151:329-37.
91. Rossi GP, Pitter G, Bernante P, Motta R, Feltrin G, Miotto D. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens. 2008;26:989-97. (Pubitemid 351520987)
92. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics. 2005;25 Suppl 1:S143-58.
93. Rossi GP, Ganzaroli C, Miotto D, De Toni R, Palumbo G, Feltrin GP, et al. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J Hypertens. 2006;24:371-9. (Pubitemid 43348251)
94. Miotto D, De Toni R, Pitter G, Seccia TM, Motta R, Vincenzi M, et al. Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism. Hypertension. 2009;54:885-9.
95. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab. 2001;86:1083-90. (Pubitemid 32322986)
96. Rossi GP. New concepts in adrenal vein sampling for aldosterone in the diagnosis of primary aldosteronism. Curr Hypertens Rep. 2007;9:90-7. (Pubitemid 46779372)
97. Rossi GP, Pitter G, Miotto D. To stimulate or not to stimulate: is adrenocorticotrophic hormone testing necessary, or not? J Hypertens. 2007;25:481-4. (Pubitemid 46071951)
98. Rossi GP, Pitter G, Miotto D. To stimulate or not to stimulate: is adrenocorticotrophic hormone testing necessary, or not? Round 2. J Hypertens. 2007;25:1518-20. (Pubitemid 46918848)
99. Seccia TM, Miotto D, De Toni R, Pitter G, Mantero F, Pessina AC, et al. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension. 2009;53:761-6.
100. Hogan MJ, McRae J, Schambelan M, Biglieri EG. Location of aldosterone-producing adenomas with 131I-19-iodocholesterol. N Engl J Med. 1976;294:410-4.
101. Nomura K, Kusakabe K, Maki M, Ito Y, Aiba M, Demura H. Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppresion scintigraphy: relationship to adenoma size and functional activity. J Clin Endocrinol Metab. 1990;71:825-30.
102. Mansoor GA, Malchoff CD, Arici MH, Karimeddini MK, Whalen GF. Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning. Am J Hypertens. 2002;15:459-64. (Pubitemid 34478486)
103. Toniato A, Bernante P, Rossi GP, Piotto A, Pelizzo MR. Laparoscopic versus open adrenalectomy: outcome in 35 consecutive patients. Int J Surg Investig. 2000;1:503-7.
104. Jeschke K, Janetschek G, Peschel R, Schellander L, Bartsch G, Henning K. Laparoscopic partial adrenalectomy in patients with aldosterone-producing adenomas: indications, technique, and results. Urology. 2003;61:69-72. (Pubitemid 36151714)
105. Meria P, Kempf BF, Hermieu JF, Plouin PF, Duclos JM. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. J Urol. 2003;169:32-5. (Pubitemid 35461542)
106. Lumachi F, Ermani M, Basso SM, Armanini D, Iacobone M, Favia G. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg. 2005;71:864-9.
107. Obara T, Ito Y, Okamoto T, Kanaji Y, Yamashita T, Aiba M, et al. Risk factors associated with postoperative persistent hypertension in patients with primary aldosteronism. Surgery. 1992;112:987-93. (Pubitemid 23008223)
108. Proye CA, Mulliez EA, Carnaille BM, Lecomte-Houcke M, Decoulx M, Wemeau JL, et al. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery. 1998;124:1128-33.
109. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008;51:742-8. (Pubitemid 351301529)
110. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010;56:831-8.